Kessler Topaz Meltzer & Check Launches Investigation into uniQure N.V.'s Recent Stock Drop and SEC Violations

Investigation into uniQure N.V. by Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is actively investigating possible breaches of federal securities laws concerning uniQure N.V., a biotechnology company listed on NASDAQ under the ticker symbol QURE. Investors are encouraged to reach out to the firm if they have faced significant financial losses due to the company's recent events. The law firm, known for representing individuals and institutions in securities fraud cases, aims to ensure that investor rights are protected.

On November 3, 2025, uniQure announced concerning news that caused a sharp decline in its stock price. The company revealed that the U.S. Food and Drug Administration (FDA) had communicated to them that the data related to their investigational gene therapy, AMT-130, for Huntington's disease, was not sufficient to support their Biologics License Application (BLA). This was a significant setback for uniQure, as they had previously expected the BLA submission to proceed successfully based on the results from ongoing Phase I/II studies.

The unexpected FDA notice indicated a lack of agreement from the agency on the adequacy of the data collected from those studies, leading uniQure to express uncertainty about the timing of the BLA submission. Following this news, uniQure's stock price plummeted more than 50%, dropping from $67.69 at the end of trading on October 31 to just $34.29 by November 3.

This drastic decrease in the stock value caught the attention of Kessler Topaz Meltzer & Check, LLP. The law firm, which prides itself on its advocacy for investors, is now looking into the circumstances surrounding uniQure's statements and the potential impact of the FDA's feedback on the stock performance. Investors who have suffered devastating losses during this period are encouraged to contact the firm to discuss their eligibility for legal recourse.

Kessler Topaz Meltzer & Check, LLP has established a reputation among legal circles as a leading plaintiff-side law firm, particularly in the realm of securities-fraud class actions and protecting global investor rights. They have successfully represented a range of clients, from individual investors to major institutional entities, and have been recognized with several accolades that underscore their commitment to ethical and effective advocacy. Some notable mentions include listings in The National Law Journal's Plaintiff's Hot List and acknowledgment as one of the most feared law firms by BTI Consulting Group.

For potential uniQure investors looking to understand their options, Kessler Topaz Meltzer & Check, LLP provides a means to learn about their investigation by simply filling out a form on their website, or by contacting them directly via phone or email. The firm assures that their outreach is based on the pursuit of justice and ensuring that investor rights are upheld in light of potential securities violations.

As the investigation unfolds, affected investors are urged to stay tuned for updates from Kessler Topaz Meltzer & Check, LLP as they work to illuminate the full extent of the situation involving uniQure N.V. and its potential implications for the future.

For more information or to participate in the investigation, investors may visit the firm's dedicated webpage on the matter or directly reach out to Jonathan Naji, Esq. at Kessler Topaz Meltzer & Check, LLP. They remain committed to serving their clients and bringing accountability to the forefront in securities law.